Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.67 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.67 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.67 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.67 |
| ▸ | PDE1A | P54750 | 9/20 | 0.61 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.61 |
| ▸ | PDE1C | Q14123 | 9/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17858206 | 1.00 | ESR1 (0.67) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17845113 | 1.00 | ESR1 (0.67) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17845211 | 1.00 | ESR1 (0.67) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17858207 | 1.00 | ESR1 (0.67) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17845112 | 1.00 | ESR1 (0.67) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17845170 | 0.96 | ESR1 (0.62) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17845169 | 0.96 | ESR1 (0.62) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL21780775 | 0.96 | ESR1 (0.62) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17845172 | 0.96 | ESR1 (0.62) | ESR1PSMB1PSMB5PSMB2PDE1A | |
| SCHEMBL17858203 | 0.96 | ESR1 (0.62) | ESR1PSMB1PSMB5PSMB2PDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ESR1 2/4885PSMB1 736/4885PSMB5 532/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ESR1 2/4885PSMB1 736/4885PSMB5 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.